JTC ORD GBP0.01 overview

Advario, VFlowTech and JTC sign MOU to accelerate deployment of clean energy storage capacity on Jurong Island by up to 25 times PR Newswire SINGAPORE, Oct. 22, 2024 SINGAPORE , Oct. 22, 2024 /PRNewswire/ -- Advario Asia Pacific (Advario), VFlowTech (VFT), and JTC today signed a Memorandum of Understanding (MoU) to collaborate on scaling up vanadium redox flow battery (VRFB) capacity for clean energy storage on Jurong Island. Under the MoU, the three parties will explore using Advario's tank...

Norlantic Capital Partners with JTC Group to Launch Norlantic ICAV, Offering Global Investors Access to the U.S. Middle Market PR Newswire DUBLIN, Oct. 7, 2024 DUBLIN , Oct. 7, 2024 /PRNewswire/ -- Norlantic Capital, a cross-border private markets firm, in collaboration with global funds specialist JTC Group, is pleased to announce the establishment of Norlantic ICAV , an umbrella type Irish collective asset-management vehicle (ICAV) authorized by the Central Bank of Ireland (Central Bank) as a...

Watch the "What This Means" segment here FRENCHTOWN, NJ / ACCESSWIRE / July 24, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means " segment featuring Sonnet BioTherapeutics, Inc. (Nasdaq:SONN), a clinical-stage company developing targeted immunotherapeutic drugs. As part of the "What This Means" segment, Pankaj Mohan, PhD, Founder and Chief Executive Officer, Richard Kenney, M.D., Chief Medical...

- Two-day conference with live video webcast presentations and Q&A beginning today, June 17 th at 9:00 AM ET - Full schedule of participating companies now available at www.virtualinvestorco.com FRENCHTOWN, NJ / ACCESSWIRE / June 17, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the final participating company line-up for the two-day Virtual Investor Pitch Conference beginning today, Monday, June 17, 2024. For the event,...

Live webcast on Thursday, June 13 th at 4:00 PM ET FRENCHTOWN, NJ / ACCESSWIRE / June 12, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced that Outlook Therapeutics, Inc. (Nasdaq:OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, will participate in the Virtual Investor Closing Bell Series on...

- Live video webcast presentations with Q&A - Preliminary schedule of participating companies now available at www.virtualinvestorco.com FRENCHTOWN, NJ / ACCESSWIRE / June 10, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor Pitch Conference on June 17-18, 2024. For the event, participating companies will provide their "elevator pitch" and outline upcoming milestones. Additionally, investors and...

Watch the "What This Means" video here Outlook CEO, Russ Trenary underscores that LYTENAVA™ (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD FRENCHTOWN, NJ / ACCESSWIRE / June 6, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Outlook Therapeutics, Inc....

- Live video webcast presentations with Q&A - Participating company line-up to be announced FRENCHTOWN, NJ / ACCESSWIRE / May 28, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor Pitch Conference on June 17-18, 2024. A full line-up of presenting companies will be announced at a later date. For the event, participating companies will provide their "elevator pitch" and outline upcoming milestones....